



NDA 022210/S-006

**FULFILLMENT OF POSTMARKETING REQUIREMENT
SUPPLEMENT APPROVAL**

Eurand Pharmaceuticals, Inc.
c/o Eurand Pharmaceuticals, Inc. U.S. Agent
Attention: Susan Thornton
Director, Regulatory Affairs
790 Township Line Road, Suite 250
Yardley, PA 19067

Dear Ms. Thornton:

Please refer to your Supplemental New Drug Application (sNDA) dated December 15, 2010, received December 16, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zenpep (pancrelipase) Delayed-Release Capsules.

We acknowledge receipt of your amendments dated February 8, February 14, February 25, April 8, April 13, May 31, June 10, and June 13, 2010.

This "Prior Approval" supplemental new drug application provides for a validation protocol for an additional dosage strength of 3,000 USP lipase units.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As provided under 21 CFR 314.70(e), approval of a protocol may justify a reduced reporting category for a particular change. If the results of the process validation study conducted to support the filling step for the 3,000 U USP Lipase/cps product meet the requirements specified in your approved protocol, it should be reported in your annual report (21 CFR 314.70(d)). This report should include the information described in 21 CFR 314.70(d)(3).

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories. Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the carton and immediate container labels submitted on December 15, 2010, as soon as they are available, but no more than 30 days after they are printed.

Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 022210/S-006.**” Approval of this submission by FDA is not required before the labeling is used.

If sending via USPS, please send to:

Brian Strongin, R.Ph., M.B.A.
Food and Drug Administration
Center for Drug Evaluation and
Research
White Oak Building 22,
Room: 5116
10903 New Hampshire Avenue
Silver Spring, Maryland 20993

If sending via any carrier other than USPS
(e.g., UPS, DHL), please send to:

Brian Strongin, R.Ph., M.B.A.
Food and Drug Administration
Center for Drug Evaluation and
Research
White Oak Building 22,
Room: 5116
10903 New Hampshire Avenue
Silver Spring, Maryland 20903

FULFILLMENT OF POSTMARKETING REQUIREMENT

We have reviewed your submission and conclude that the following requirement was fulfilled.

REQUIRED PEDIATRIC ASSESSMENTS

- 1521-1 Deferred requirement for development of an age appropriate formulation for Zenpep (pancrelipase) Delayed-Release Capsules: Develop an age appropriate formulation to allow for dosing to the youngest, lowest weight pediatric patients, including infants less than 12 months of age who will be administered 2,000 to 4,000 lipase units per 120 mL of formula or per breast-feeding.

We remind you that there are postmarketing requirement(s) **AND** postmarketing commitment(s) listed in the April 30, 2009 approval letter that are still open.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Brian Strongin, R.Ph., M.B.A., Chief, Regulatory Project Management Staff, at (301) 796-1008.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D.
Deputy Director for Safety
Division of Gastroenterology and
Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
06/15/2011